Abnormal α-synuclein aggregation has been implicated in several neurodegenerative diseases and is known to spread in a prion-like manner. There is a relationship between protein aggregate structure (strain) and clinical phenotype in prion diseases, however, whether differences in the strains of α synuclein aggregates account for the different pathologies remained unclear. Researchers in Tokyo Metropolitan Institute of Medical Science (TMIMS) discovered a possible molecular mechanism to account for the different pathologies induced by different α synuclein strains.
Parkinson's disease is most commonly treated with levodopa, but the benefits wear off as the disease progresses and high doses can result in dyskinesia, which are involuntary and uncontrollable movements. To better understand the underlying reasons behind these effects, researchers created a model of the interactions between levodopa, dopamine, and the basal ganglia, an area of the brain that plays a crucial role in Parkinson's disease. They discuss their findings in the journal Chaos.
A team of researchers in the United States and Japan reports that spinal cord stimulation (SCS) measurably decreased pain and reduced motor symptoms of Parkinson's disease, both as a singular therapy and as a 'salvage therapy' after deep brain stimulation (DBS) therapies were ineffective.
University of Wisconsin-Madison researchers demonstrated a proof-of-concept stem cell treatment in a mouse model of Parkinson's disease. They found that neurons derived from stem cells can integrate well into the correct regions of the brain, connect with native neurons and restore motor functions.
Well over six million people globally have been diagnosed with Parkinson's disease, which has an enormous impact on the lives of patients and their families and incurring mounting costs for society. In this special supplement to the Journal of Parkinson's Disease experts review common and vexing issues affecting people with Parkinson's disease as well as emerging concerns such as the importance of personalized care management.
A research team from Kumamoto University, Japan has developed an animal model that reproduces motor dysfunction and cerebellar neurodegeneration similar to that in spinocerebellar ataxia (SCA) by inhibiting chaperone-mediated autophagy (CMA) in cerebellar neurons. Since CMA activity is reduced in cells expressing SCA causing proteins, CMA is expected to become a new therapeutic target for SCA--a disease that currently has no basic treatment.
Is the world prepared a wave of neurological consequences that may be on its way as a result of COVID-19? This question is at the forefront of research underway at the Florey Institute of Neuroscience and Mental Health. A team of neuroscientists and clinicians are examining the potential link between COVID-19 and increased risk of Parkinson's disease, and measures to get ahead of the curve.
Researchers around the world have been puzzled by the different symptoms and varied disease pathways of Parkinson's patients. A major study from Aarhus University, Denmark, has now identified that there are actually two types of the disease.
A global survey of health professionals has shown that during the COVID-19 pandemic, patients with Parkinson's disease in large parts of Asia, Africa, and Latin and South America experienced difficulty in accessing their medication, which is likely to have led to deterioration of symptom control.
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders. The system, which uses extremely thin biomaterials implanted in the body, also protects nerve fibers (axons) that connect nerve cells in injured neural tissues, according to a study in the journal Advanced Materials.